Anti-dengue antibody therapeutic - Mabloc
Latest Information Update: 23 Jan 2026
At a glance
- Originator Mabloc
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dengue
Most Recent Events
- 16 Dec 2025 Preclinical trials in Dengue in USA (Parenteral) prior to December 2025 (Mabloc pipeline, December 2025)